HAB PHARMAHAB PHARMA

Drug Discovery

AB Pharmaceuticals & Research Ltd. is presently focused on generating novel small molecule therapies for indications in three therapeutic area clusters: Metabolic Diseases, Inflammatory Diseases, and Neglected Diseases of the developing world.

Project oriented multidisciplinary teams consisting of medicinal chemists, molecular and cell biologists, biochemists, pharmacologists, physiologists and pharmaceutical scientists direct programs from hit to lead clinical candidates. Preclinical and early clinical development is also carried out by the team. Its collaborative drug discovery activity generates intellectual property that will be available for licensing at any stage from clinical candidacy onward.

HAB’s formulation development department has in a short span of time obtained a large number of “New Drug Approvals” (about 50) from Drug Controller General of India and is in the process of getting more New Drug Approvals.